Literature DB >> 10817728

Therapeutic responses to different antimalarial drugs in vivax malaria.

S Pukrittayakamee1, A Chantra, J A Simpson, S Vanijanonta, R Clemens, S Looareesuwan, N J White.   

Abstract

The therapeutic responses to the eight most widely used antimalarial drugs were assessed in 207 adult patients with Plasmodium vivax malaria. This parasite does not cause marked sequestration, so parasite clearance can be used as a direct measure of antimalarial activity. The activities of these drugs in descending order were artesunate, artemether, chloroquine, mefloquine, quinine, halofantrine, primaquine, and pyrimethamine-sulfadoxine (PS). Therapeutic responses to PS were poor; parasitemias did not clear in 5 of the 12 PS-treated patients, whereas all the other patients made an initial recovery. Of 166 patients monitored for > or =28 days, 35% had reappearance of vivax malaria 11 to 65 days later and 7% developed falciparum malaria 5 to 21 days after the start of treatment. There were no significant differences in the times taken for vivax malaria reappearance among the different groups except for those given mefloquine and chloroquine, in which all vivax malaria reappearances developed >28 days after treatment, suggesting suppression of the first relapse by these slowly eliminated drugs. There was no evidence of chloroquine resistance. The antimalarial drugs vary considerably in their intrinsic activities and stage specificities of action.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817728      PMCID: PMC89932          DOI: 10.1128/AAC.44.6.1680-1685.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Pulmonary oedema in vivax malaria.

Authors:  S Pukrittayakamee; A Chantra; S Vanijanonta; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1998 Jul-Aug       Impact factor: 2.184

2.  Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker.

Authors:  K Kirchgatter; H A del Portillo
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

Review 3.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo.

Authors:  N J White
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria.

Authors:  R N Price; F Nosten; C Luxemburger; M van Vugt; L Phaipun; T Chongsuphajaisiddhi; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Sep-Oct       Impact factor: 2.184

5.  Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria.

Authors:  N J White; S Krishna; D Waller; C Craddock; D Kwiatkowski; D Brewster
Journal:  Lancet       Date:  1989-12-02       Impact factor: 79.321

6.  Comparative efficacies of quinine and chloroquine as companions to primaquine in a curative drug regimen.

Authors:  L H Schmidt
Journal:  Am J Trop Med Hyg       Date:  1981-01       Impact factor: 2.345

7.  Treatment of vivax malaria on the western border of Thailand.

Authors:  C Luxemburger; M van Vugt; S Jonathan; R McGready; S Looareesuwan; N J White; F Nosten
Journal:  Trans R Soc Trop Med Hyg       Date:  1999 Jul-Aug       Impact factor: 2.184

Review 8.  Primaquine resistance in Plasmodium vivax.

Authors:  W E Collins; G M Jeffery
Journal:  Am J Trop Med Hyg       Date:  1996-09       Impact factor: 2.345

9.  Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance.

Authors:  P E de Pécoulas; R Tahar; T Ouatas; A Mazabraud; L K Basco
Journal:  Mol Biochem Parasitol       Date:  1998-05-01       Impact factor: 1.759

10.  Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.

Authors:  S Pukrittayakamee; S Vanijanonta; A Chantra; R Clemens; N J White
Journal:  J Infect Dis       Date:  1994-04       Impact factor: 5.226

View more
  88 in total

Review 1.  Chemotherapeutic hope on the horizon for Plasmodium vivax malaria?

Authors:  Robert G Ridley
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand.

Authors:  Mallika Imwong; Sasithon Pukrittayakamee; Qin Cheng; Catrin Moore; Sornchai Looareesuwan; Georges Snounou; Nicholas J White; Nicholas P J Day
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Current challenges in travelers' malaria.

Authors:  Patricia Schlagenhauf; Eskild Petersen
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

4.  Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.

Authors:  Patricia Mula; Amalia Fernández-Martínez; Aida de Lucio; Jose Manuel Ramos; Francisco Reyes; Vicenta González; Agustín Benito; Pedro Berzosa
Journal:  Malar J       Date:  2011-08-02       Impact factor: 2.979

Review 5.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

Review 6.  Resistance to therapies for infection by Plasmodium vivax.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

7.  Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates.

Authors:  M Imwong; S Pukrittakayamee; S Looareesuwan; G Pasvol; J Poirreiz; N J White; G Snounou
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia.

Authors:  Inge Sutanto; Bagus Tjahjono; Hasan Basri; W Robert Taylor; Fauziah A Putri; Rizka A Meilia; Rianto Setiabudy; Siti Nurleila; Lenny L Ekawati; Iqbal Elyazar; Jeremy Farrar; Herawati Sudoyo; J Kevin Baird
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

9.  Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand.

Authors:  Udomsak Silachamroon; Srivicha Krudsood; Sombat Treeprasertsuk; Polrat Wilairatana; Kobsiri Chalearmrult; Hla Yin Mint; Pannamas Maneekan; Nicholas J White; Victor R Gourdeuk; Gary M Brittenham; Sornchai Looareesuwan
Journal:  Am J Trop Med Hyg       Date:  2003-07       Impact factor: 2.345

10.  Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial.

Authors:  Ghulam Rahim Awab; Sasithon Pukrittayakamee; Mallika Imwong; Arjen M Dondorp; Charles J Woodrow; Sue Jean Lee; Nicholas P J Day; Pratap Singhasivanon; Nicholas J White; Faizullah Kaker
Journal:  Malar J       Date:  2010-04-21       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.